Complimentary access to the JTO and a 15% discount on the publication fees for the newest open-access IASLC journal, JTO CRR. Both JTO and JTO CRR feature novel research about the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO is among the top 5% of all oncology journals and the leading journal that is entirely focused on thoracic oncology.
JTO and JTO CRR feature novel research about the prevention, detection, diagnosis, and treatment of all thoracic malignancies. With an Impact Factor of 21.0, JTO is among the top 4% of all oncology journals and the leading journal that is entirely focused on thoracic oncology. It emphasizes a multidisciplinary approach and includes original research, reviews, and opinion pieces. JTO CRR, IASLC’s open-access companion title, publishes a range of manuscripts, from subset analyses of published trials to high-quality case reports. JTO CRR has an Impact Factor of 3.0 and is indexed in PubMed and Web of Science.
JTO by the Numbers
13
out of 322 in Oncology Journals
2
out of 100 in Respiratory Journals
21.0
Impact Factor (up from 20.4 in 2022)
1,704%
increase in 6 years full-text article downloads
EDITOR-IN-CHIEF, JTO ON 2023 IMPACT FACTOR
Alex A. Adjei, MD, PhD, FACP
"JTO's impact factor for 2023 has risen to 21, making it only the second respiratory journal (after Lancet Respiratory Medicine) with an impact factor above 20. More importantly, it is the only thoracic oncology journal with an impact factor greater than 10. This is a notable achievement since we are a sub-specialty journal dealing with only thoracic oncology. There are no other sub-specialty journals among the top 20 oncology journals, and we now rank 13th out of 322 oncology journals. This achievement is a testament to the exemplary work of our editorial board and our editorial office, as well as the support of IASLC—its executives, office staff, membership, and above all, our reviewers, readers, and authors. JTO will continue its emphasis on multidisciplinary research to serve the broad community working in thoracic oncology."
JTO CRR By the Numbers
142
out of 322 Oncology Journals
37
out of 100 Respiratory Journals
3.0
2023 Impact Factor
EDITOR-IN-CHIEF, JTO CRR ON 2023 IMPACT FACTOR
Emily Stone, MBBS, PhD, FRACP
“The JTO CRR team is celebrating our first impact factor at 3.0, and we wish to thank everyone who made it possible – the authors, reviewers, editors, and the IASLC. We are thrilled to make such a terrific start, which truly reflects our commitment to excellence in science.”
Most-Cited Journal of Thoracic Oncology Articles in 2023
The 2021 WHO Classification of Lung Tumors: Impact of advances since 2015
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial
Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11 and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status
Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC
Recent journal articles
FGTI-2734 Inhibits ERK Reactivation to Overcome Sotorasib Resistance in KRAS G12C Lung Cancer
Identification of defined molecular subgroups based on immunohistochemical analyses and potential therapeutic vulnerabilities of pulmonary carcinoids
Polygenic risk score and lung adenocarcinoma risk among never-smokers by EGFR mutation status-a brief report
Low dose computed tomography for lung cancer screening in Tuberculosis endemic countries: A Systematic Review and Meta-analysis
Brief Report: Final overall survival and long-term safety of lorlatinib in patients with ALK-positive non-small cell lung cancer from the pivotal phase 2 study
Durvalumab, tremelimumab and platinum chemotherapy in EGFR mutation positive non-small cell lung cancer - an open label phase 2 trial (ILLUMINATE)
MYASTHENIA GRAVIS IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS
Personalized Therapy in a Patient with EGFR-Mutated NSCLC Developing Sequential CCDC6-RET Fusion and BRAF V600E Mutation as Bypass Resistance Mechanisms.
Discover the JTO
JTO.org offers numerous ways to stay abreast of novel research and information vital to your daily oncology practice. Join the JTO reader community to:
More than 80 international experts compose the JTO Editorial Board, allowing for a quick turn-around time of 1 week to initial decision, and an average of 1.6 weeks for revisions, a fast track category, publish on acceptance (within 5 days), and promotion of select articles via social media and press releases.
JTO emphasizes a multidisciplinary approach and includes original research (clinical trials and translational or basic research), reviews, and opinion pieces. Authors can take advantage of Elsevier's Researcher Academy, Navigate your research journey with Researcher Academy—free e-learning modules on navigating your career developed by global experts.
JTO reviewers are given the privilege of getting the first look at novel research, phase III data, and potentially practice-changing concepts. Email your CV to JTO@iaslc.org.
New JTO Collections
Discover the JTO CRR
Providing a more clinical focus, the JTO CRR contains phase I thoracic oncology clinical trials and single-arm phase II trials, as well as case reports, subset analyses of a published trials, database analyses, retrospective trials, and large single-institution series.
In addition to the content discussed previously, JTO CRR also accepts region-specific clinical trials, subspecialty thoracic oncology studies, and select high-quality meeting reports.
To become a JTO CRR Reviewer email your CV to JTOCRR@iaslc.org.
Related Content
